{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:13:14Z","timestamp":1780395194744,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm Regener"],"DOI":"10.1186\/s41232-026-00425-5","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:02:36Z","timestamp":1780106556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Generation of therapeutic T cells from human induced pluripotent stem cells"],"prefix":"10.1186","volume":"46","author":[{"given":"Bo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"425_CR1","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135. https:\/\/doi.org\/10.1126\/science.aar6711.","journal-title":"Science"},{"key":"425_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492\u20139. https:\/\/doi.org\/10.1038\/ni.2035.","journal-title":"Nat Immunol"},{"key":"425_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371. https:\/\/doi.org\/10.1038\/s41591-018-0010-1.","journal-title":"Nat Med"},{"key":"425_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s40883-019-00124-3","volume":"6","author":"AD Fesnak","year":"2020","unstructured":"Fesnak AD. The challenge of variability in chimeric antigen receptor T cell manufacturing. Regen Eng Transl Med. 2020;6:322\u20139. https:\/\/doi.org\/10.1007\/s40883-019-00124-3.","journal-title":"Regen Eng Transl Med"},{"key":"425_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861\u201372. https:\/\/doi.org\/10.1016\/j.cell.2007.11.019.","journal-title":"Cell"},{"key":"425_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","volume":"12","author":"T Nishimura","year":"2013","unstructured":"Nishimura T, Kaneko S, Kawana-Tachikawa A, et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013;12:114\u201326. https:\/\/doi.org\/10.1016\/j.stem.2012.11.002.","journal-title":"Cell Stem Cell"},{"key":"425_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stem.2012.12.006","volume":"12","author":"R Vizcardo","year":"2013","unstructured":"Vizcardo R, Masuda K, Yamada D, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8 + T cells. Cell Stem Cell. 2013;12:31\u20136. https:\/\/doi.org\/10.1016\/j.stem.2012.12.006.","journal-title":"Cell Stem Cell"},{"key":"425_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101109","volume":"31","author":"S Takayanagi","year":"2023","unstructured":"Takayanagi S, Wang B, Hasegawa S, et al. Mini-TCRs: truncated T cell receptors to generate T cells from induced pluripotent stem cells. Mol Ther Methods Clin Dev. 2023;31:101109. https:\/\/doi.org\/10.1016\/j.omtm.2023.101109.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"425_CR9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.stem.2018.10.005","volume":"23","author":"A Minagawa","year":"2018","unstructured":"Minagawa A, Yoshikawa T, Yasukawa M, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell. 2018;23:850-858.e4. https:\/\/doi.org\/10.1016\/j.stem.2018.10.005.","journal-title":"Cell Stem Cell"},{"key":"425_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","volume":"5","author":"B Wang","year":"2021","unstructured":"Wang B, Iriguchi S, Waseda M, et al. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat Biomed Eng. 2021;5:429\u201340. https:\/\/doi.org\/10.1038\/s41551-021-00730-z.","journal-title":"Nat Biomed Eng"},{"key":"425_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02195-x","volume":"4","author":"T Ito","year":"2021","unstructured":"Ito T, Kawai Y, Yasui Y, et al. The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-derived iPS cells. Commun Biol. 2021;4:694. https:\/\/doi.org\/10.1038\/s42003-021-02195-x.","journal-title":"Commun Biol"},{"key":"425_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20658-3","volume":"12","author":"S Iriguchi","year":"2021","unstructured":"Iriguchi S, Yasui Y, Kawai Y, et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat Commun. 2021;12:430. https:\/\/doi.org\/10.1038\/s41467-020-20658-3.","journal-title":"Nat Commun"},{"key":"425_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-022-00969-0","author":"T Ueda","year":"2022","unstructured":"Ueda T, Shiina S, Iriguchi S, et al. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat Biomed Eng. 2022. https:\/\/doi.org\/10.1038\/s41551-022-00969-0.","journal-title":"Nat Biomed Eng"},{"key":"425_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2026.101060","volume":"31","author":"J Zhang","year":"2026","unstructured":"Zhang J, Sumide K, Kanie K, et al. Immune synapse molecules knockout in induced pluripotent stem cells enables broad NK cell resistance in T cell progeny. Regen Ther. 2026;31:101060. https:\/\/doi.org\/10.1016\/j.reth.2026.101060.","journal-title":"Regen Ther"},{"key":"425_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.102001","volume":"28","author":"C Zhang","year":"2026","unstructured":"Zhang C, Rassner M, Kawai Y, et al. Chimeric synthetic T cell receptor and antigen receptor receptors enable high-sensitivity T cell receptor-negative CD8\u03b1\u03b2-CD3-positive T-cell development from human-induced pluripotent stem cells. Cytotherapy. 2026;28:102001. https:\/\/doi.org\/10.1016\/j.jcyt.2025.102001.","journal-title":"Cytotherapy"},{"key":"425_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.stem.2024.05.004","volume":"31","author":"H Yano","year":"2024","unstructured":"Yano H, Koga K, Sato T, et al. Human iPSC-derived CD4+ Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model. Cell Stem Cell. 2024;31:795-802.e6. https:\/\/doi.org\/10.1016\/j.stem.2024.05.004.","journal-title":"Cell Stem Cell"},{"key":"425_CR17","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.stemcr.2018.04.025","volume":"10","author":"N Ueda","year":"2018","unstructured":"Ueda N, Uemura Y, Zhang R, et al. Generation of TCR-expressing innate lymphoid-like helper cells that induce cytotoxic T cell-mediated anti-leukemic cell response. Stem Cell Rep. 2018;10:1935\u201346. https:\/\/doi.org\/10.1016\/j.stemcr.2018.04.025.","journal-title":"Stem Cell Rep"},{"key":"425_CR18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","volume":"31","author":"M Themeli","year":"2013","unstructured":"Themeli M, Kloss CC, Ciriello G, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31:928\u201333. https:\/\/doi.org\/10.1038\/nbt.2678.","journal-title":"Nat Biotechnol"},{"key":"425_CR19","doi-asserted-by":"crossref","unstructured":"Iriguchi S, Yasui Y, Kawai Y, et al. Feeder-free differentiation and expansion for T cells from induced pluripotent stem cells.\u00a0Protoc Exch. 2020.","DOI":"10.21203\/rs.3.pex-1271\/v1"},{"key":"425_CR20","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1016\/j.ymthe.2021.05.016","volume":"29","author":"Y Kawai","year":"2021","unstructured":"Kawai Y, Kawana-Tachikawa A, Kitayama S, et al. Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy. Mol Ther. 2021;29:3027\u201341. https:\/\/doi.org\/10.1016\/j.ymthe.2021.05.016.","journal-title":"Mol Ther"},{"key":"425_CR21","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1172\/JCI126350","volume":"129","author":"M Maluski","year":"2019","unstructured":"Maluski M, Ghosh A, Herbst J, et al. Chimeric antigen receptor\u2013induced BCL11B suppression propagates NK-like cell development. J Clin Invest. 2019;129:5108\u201322. https:\/\/doi.org\/10.1172\/JCI126350.","journal-title":"J Clin Invest"},{"key":"425_CR22","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1158\/0008-5472.CAN-12-3874","volume":"73","author":"MJ Riese","year":"2013","unstructured":"Riese MJ, Wang L-CS, Moon EK, et al. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res. 2013;73:3566\u201377. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3874.","journal-title":"Cancer Res"},{"key":"425_CR23","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1158\/0008-5472.CAN-18-0030","volume":"78","author":"I-Y Jung","year":"2018","unstructured":"Jung I-Y, Kim Y-Y, Yu H-S, et al. CRISPR\/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res. 2018;78:4692\u2013703. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0030.","journal-title":"Cancer Res"},{"key":"425_CR24","doi-asserted-by":"publisher","unstructured":"M\u00e9rida I, Andrada E, Gharbi SI, \u00c1vila-Flores A (2015) Redundant and specialized roles for diacylglycerol kinases \u03b1 and \u03b6 in the control of T cell functions. Sci Signal 8:. https:\/\/doi.org\/10.1126\/scisignal.aaa0974","DOI":"10.1126\/scisignal.aaa0974"},{"key":"425_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nmeth.1591","volume":"8","author":"K Okita","year":"2011","unstructured":"Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8:409\u201312. https:\/\/doi.org\/10.1038\/nmeth.1591.","journal-title":"Nat Methods"},{"key":"425_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.stem.2012.07.014","volume":"11","author":"CJ Taylor","year":"2012","unstructured":"Taylor CJ, Peacock S, Chaudhry AN, et al. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell. 2012;11:147\u201352. https:\/\/doi.org\/10.1016\/j.stem.2012.07.014.","journal-title":"Cell Stem Cell"},{"key":"425_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.medj.2022.10.003","volume":"4","author":"S Yoshida","year":"2023","unstructured":"Yoshida S, Kato TM, Sato Y, et al. A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population. Med. 2023;4:51-66.e10. https:\/\/doi.org\/10.1016\/j.medj.2022.10.003.","journal-title":"Med"},{"key":"425_CR28","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/cas.14374","volume":"111","author":"T Ueda","year":"2020","unstructured":"Ueda T, Kumagai A, Iriguchi S, et al. Non\u2013clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti\u2013glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells. Cancer Sci. 2020;111:1478\u201390. https:\/\/doi.org\/10.1111\/cas.14374.","journal-title":"Cancer Sci"},{"key":"425_CR29","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","volume":"35","author":"GG Gornalusse","year":"2017","unstructured":"Gornalusse GG, Hirata RK, Funk SE, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017;35:765\u201372. https:\/\/doi.org\/10.1038\/nbt.3860.","journal-title":"Nat Biotechnol"},{"key":"425_CR30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","volume":"24","author":"H Xu","year":"2019","unstructured":"Xu H, Wang B, Ono M, et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell. 2019;24:566-578.e7. https:\/\/doi.org\/10.1016\/j.stem.2019.02.005.","journal-title":"Cell Stem Cell"},{"key":"425_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","volume":"37","author":"T Deuse","year":"2019","unstructured":"Deuse T, Hu X, Gravina A, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019;37:252\u20138. https:\/\/doi.org\/10.1038\/s41587-019-0016-3.","journal-title":"Nat Biotechnol"},{"key":"425_CR32","doi-asserted-by":"publisher","first-page":"10441","DOI":"10.1073\/pnas.1902566116","volume":"116","author":"X Han","year":"2019","unstructured":"Han X, Wang M, Duan S, et al. Generation of hypoimmunogenic human pluripotent stem cells. Proc Natl Acad Sci U S A. 2019;116:10441\u20136. https:\/\/doi.org\/10.1073\/pnas.1902566116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"425_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41232-020-00132-9","volume":"40","author":"K Koga","year":"2020","unstructured":"Koga K, Wang B, Kaneko S. Current status and future perspectives of HLA-edited induced pluripotent stem cells. Inflamm Regen. 2020;40:23. https:\/\/doi.org\/10.1186\/s41232-020-00132-9.","journal-title":"Inflamm Regen"},{"key":"425_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5191","volume":"13","author":"Y Liu","year":"2021","unstructured":"Liu Y, Liu G, Wang J, et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med. 2021;13:eabb5191. https:\/\/doi.org\/10.1126\/scitranslmed.abb5191.","journal-title":"Sci Transl Med"},{"key":"425_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","volume":"28","author":"J Mansilla-Soto","year":"2022","unstructured":"Mansilla-Soto J, Eyquem J, Haubner S, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med. 2022;28:345\u201352. https:\/\/doi.org\/10.1038\/s41591-021-01621-1.","journal-title":"Nat Med"},{"key":"425_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114949","volume":"43","author":"D Huang","year":"2024","unstructured":"Huang D, Li Y, Rui W, et al. TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens. Cell Rep. 2024;43:114949. https:\/\/doi.org\/10.1016\/j.celrep.2024.114949.","journal-title":"Cell Rep"},{"key":"425_CR37","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","volume":"117","author":"M Di Ianni","year":"2011","unstructured":"Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117:3921\u20138. https:\/\/doi.org\/10.1182\/blood-2010-10-311894.","journal-title":"Blood"},{"key":"425_CR38","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.4237","volume":"14","author":"CS Seet","year":"2017","unstructured":"Seet CS, He C, Bethune MT, et al. Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids. Nat Methods. 2017;14:521\u201330. https:\/\/doi.org\/10.1038\/nmeth.4237.","journal-title":"Nat Methods"},{"key":"425_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303713","volume":"14","author":"Y Ishiguro","year":"2023","unstructured":"Ishiguro Y, Iriguchi S, Asano S, et al. Lineage tracing of T cell differentiation from T-iPSC by 2D feeder-free culture and 3D organoid culture. Front Immunol. 2023;14:1303713. https:\/\/doi.org\/10.3389\/fimmu.2023.1303713.","journal-title":"Front Immunol"},{"key":"425_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-025-00402-4","volume":"46","author":"Q Guo","year":"2026","unstructured":"Guo Q, Zhang C, Wang B, et al. Adaptive-like CAR-iPSC-CD4+ T cells outperform CD8+ counterparts in sustained ALL control. Inflamm Regen. 2026;46:4. https:\/\/doi.org\/10.1186\/s41232-025-00402-4.","journal-title":"Inflamm Regen"},{"key":"425_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw2707","volume":"4","author":"M Akamatsu","year":"2019","unstructured":"Akamatsu M, Mikami N, Ohkura N, et al. Conversion of antigen-specific effector\/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8\/19. Sci Immunol. 2019;4:eaaw2707. https:\/\/doi.org\/10.1126\/sciimmunol.aaw2707.","journal-title":"Sci Immunol"},{"key":"425_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156311","volume":"11","author":"X He","year":"2016","unstructured":"He X, Landman S, Bauland SCG, et al. A TNFR2-agonist facilitates high purity expansion of human low purity Treg cells. PLoS ONE. 2016;11:e0156311. https:\/\/doi.org\/10.1371\/journal.pone.0156311.","journal-title":"PLoS ONE"},{"key":"425_CR43","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","volume":"105","author":"M Battaglia","year":"2005","unstructured":"Battaglia M, Stabilini A, Roncarolo M-G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005;105:4743\u20138. https:\/\/doi.org\/10.1182\/blood-2004-10-3932.","journal-title":"Blood"},{"key":"425_CR44","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/ni.1677","volume":"9","author":"V Dardalhon","year":"2008","unstructured":"Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-\u03b2-induced Foxp3+ T cells and, together with TGF-\u03b2, generates IL-9+ IL-10+ Foxp3\u2212 effector T cells. Nat Immunol. 2008;9:1347\u201355. https:\/\/doi.org\/10.1038\/ni.1677.","journal-title":"Nat Immunol"},{"key":"425_CR45","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4049\/jimmunol.1200633","volume":"189","author":"R Haque","year":"2012","unstructured":"Haque R, Lei F, Xiong X, et al. Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity. J Immunol. 2012;189:1228\u201336. https:\/\/doi.org\/10.4049\/jimmunol.1200633.","journal-title":"J Immunol"},{"key":"425_CR46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2016.06.019","volume":"19","author":"M Nishizawa","year":"2016","unstructured":"Nishizawa M, Chonabayashi K, Nomura M, et al. Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity. Cell Stem Cell. 2016;19:341\u201354. https:\/\/doi.org\/10.1016\/j.stem.2016.06.019.","journal-title":"Cell Stem Cell"},{"key":"425_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202400072","volume":"46","author":"KK Hui","year":"2024","unstructured":"Hui KK, Yamanaka S. iPS cell therapy 2.0: preparing for next\u2010generation regenerative medicine. BioEssays. 2024;46:2400072. https:\/\/doi.org\/10.1002\/bies.202400072.","journal-title":"BioEssays"},{"key":"425_CR48","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nbt.2915","volume":"32","author":"CM Sturgeon","year":"2014","unstructured":"Sturgeon CM, Ditadi A, Awong G, et al. Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells. Nat Biotechnol. 2014;32:554\u201361. https:\/\/doi.org\/10.1038\/nbt.2915.","journal-title":"Nat Biotechnol"},{"key":"425_CR49","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/s41587-024-02360-7","volume":"43","author":"ES Ng","year":"2025","unstructured":"Ng ES, Sarila G, Li JY, et al. Long-term engrafting multilineage hematopoietic cells differentiated from human induced pluripotent stem cells. Nat Biotechnol. 2025;43:1274\u201387. https:\/\/doi.org\/10.1038\/s41587-024-02360-7.","journal-title":"Nat Biotechnol"},{"key":"425_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2025.101272","volume":"6","author":"ES Philonenko","year":"2026","unstructured":"Philonenko ES, Zhang B, Albert E, et al. Generation of thymus-reconstituting T cell progenitors from human pluripotent stem cells. Cell Rep Methods. 2026;6:101272. https:\/\/doi.org\/10.1016\/j.crmeth.2025.101272.","journal-title":"Cell Rep Methods"},{"key":"425_CR51","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.stemcr.2015.07.011","volume":"5","author":"M Ando","year":"2015","unstructured":"Ando M, Nishimura T, Yamazaki S, et al. A safeguard system for induced pluripotent stem cell-derived rejuvenated T cell therapy. Stem Cell Rep. 2015;5:597\u2013608. https:\/\/doi.org\/10.1016\/j.stemcr.2015.07.011.","journal-title":"Stem Cell Rep"},{"key":"425_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070543","volume":"8","author":"T-T Lim","year":"2013","unstructured":"Lim T-T, Geisen C, Hesse M, et al. Lentiviral vector mediated thymidine kinase expression in pluripotent stem cells enables removal of tumorigenic cells. PLoS ONE. 2013;8:e70543. https:\/\/doi.org\/10.1371\/journal.pone.0070543.","journal-title":"PLoS ONE"}],"container-title":["Inflammation and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41232-026-00425-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-026-00425-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-026-00425-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:24:59Z","timestamp":1780392299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41232-026-00425-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["425"],"URL":"https:\/\/doi.org\/10.1186\/s41232-026-00425-5","relation":{},"ISSN":["1880-8190"],"issn-type":[{"value":"1880-8190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shin Kaneko is a founder, shareholder, and director of Shinobi Therapeutics Inc. S.K. has also received research funding from Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., Panasonic Corporation, Mitsui-soko Co., Ltd., KOTAI Biotechnologies, and Shinobi Therapeutics Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}